With the participation of more than 80 Japanese companies, this investment promotion event held in Lecheng was "full to bursting"!
Lecheng Pilot Zone becomes “off the charts” in the hot summer. In the afternoon of July 29th, Hainan Boao Lecheng International Medical Tourism Pilot Zone Japan International Investment Promotion Conference was held in Lecheng Pilot Zone. More than 80 well-known Japanese pharmaceutical companies, investment firms, medical institutions, representatives from associations and societies, and more than 200 guests attended the conference online and offline.
The Japan International Investment Promotion Conference is targeted at Japanese medical institutions, medical device and drug manufacturers and medical service organizations, aiming at giving full play to the policy advantages of Lecheng Pilot Zone in clinical need of imported medical devices and drugs and real-world research, continuously introducing high-quality medical and health resources, speeding up the use of foreign innovative medical devices and drugs in Lecheng Pilot Zone and promoting their registration and marketing in China, so as to inject new vitality into the high-quality development of Lecheng Pilot Zone.
Jia Ning, Party Secretary and Director of Lecheng Pilot Zone Administration, pointed out in his opening speech that under the superposition of Hainan Free Trade Port, the Double State Nine Policies and other policies, Boao Lecheng has been continuously expanded its brand effect, and has become a new paradise for biomedical industry, where both domestic and foreign pharmaceutical enterprises, medical institutions, medical colleges, CRO organizations and other high-quality industrial resources have gathered one after another, boosting Lecheng from a policy highland to an industrial innovation and development highland. He said，"This year is a critical year for the construction of Hainan Free Trade Port and a crucial year for the high-quality development of Lecheng Pilot Zone. Here, we sincerely invite representatives of Japanese entrepreneurs to visit Lecheng for exchange and seek common development. Lecheng Pilot Zone Administration will definitely take the highest efficiency, the best policy and the most practical measures, and strive to create a best business environment, so that projects will be implemented in the first time so as to benefit enterprises in the first time. "
Xu Lan, member of the Party Leadership Group and Deputy Director of the Development and Reform Commission of Hainan Province, mentioned that with the continuous promotion of the construction of Hainan Free Trade Port and the continuous release of policy dividends, Hainan has continuously optimized its business environment, providing pharmaceutical enterprises with a good industrial development environment and greater development opportunities. As an authority having jurisdiction over Lecheng Pilot Zone, the Development and Reform Commission of Hainan Province will continue to make Lecheng Pilot Zone a gateway for international advanced drugs and devices to enter China, so that more innovative drugs and devices can provide better protection for people's life and health.
Zhang Yuhui, member of the Party Committee and Deputy Director of Hainan Provincial Health Commission, introduced that Lecheng Pilot Zone is the core for the development of Hainan's health industry. Hainan Provincial Health Commission, guided by system integration and innovation, will accelerate decentralization, innovate regulatory mode, speed up the implementation of preferential policies, actively introduced high-quality medical resources at home and abroad, and help Lecheng Pilot Zone to basically realize the "three synchronizations" of medical technology and equipment with the international advanced level.
Wang Gang, member of the Party Leadership Group and Deputy Director of Hainan Medical Products Administration, said that in order to give full play to the spillover effect of licensed medical devices and drugs and real-world research policies, the technical departments of NMPA and Hainan Medical Products Administration have established a smooth communication mechanism. Lecheng is a paradise for business, and a hot land for entrepreneurs. Japanese companies attending the conference are welcome to visit Lecheng for investment and participating in the construction and development of Lecheng.
ABE Takayuki, Commercial Consul of the Consulate General of Japan in Guangzhou, said that Lecheng Pilot Zone has developed into an international medical tourism service industry cluster focusing on licensed medical treatment, health management and beauty. Japanese companies are expected to have a deeper understanding of Lecheng Medical Pilot Zone via this investment promotion conference, seize new business opportunities and share the development opportunities and achievements of Hainan Free Trade Port.
Subsequently, Fu Zhu, member of the Party Committee and deputy director of Lecheng Pilot Zone Administration, Bo Pei, senior international affairs officer of Lecheng Pilot Zone Administration, and Gao Jie, head of the Investment Department of Hainan Provincial Bureau of International Economic Development, introduced the preferential policies that are available to Hainan Free Trade Port and Lecheng Pilot Zone.
Hamaguchi Hiroshi, Chairman and General Manager of Astellas Pharma China and President of Greater China Commercial, Fan Yu, President of Towako Group China, Naoki Kawamoto, Vice President of Santen Pharmaceutical (China) Co., Ltd., and Zhu Fangming, the Greater China representative of Tsurumatsu Health shared their investment and cooperation experience with Lecheng Pilot Zone.
"Can you introduce the specific process of the introduction of licensed drugs and devices in detail?" "What kind of medical device products are suitable for real-world research in Lecheng?" "Can licensed drugs and devices be used in all medical institutions in the zone after being approved for the first time?" "What is the communication mechanism after a drug or device is approved for the real world research pilot project?"... In the question-and-answer interactive session, representatives of Japanese companies attending the conference enthusiastically asked questions, and responsible persons of the Development and Reform Commission of Hainan Province, Hainan Medical Products Administration, Lecheng Pilot Zone Administration and Lecheng Medical Products Administration gave detailed answers one by one.
Fu Mingchao, chairman and president of Japan's Hainan Chamber of Commerce, said in an interview that Japan's medical industry is well developed, and Lecheng Pilot Zone is a window for China's reform and opening up in the medical field, and expected both sides would take this conference as an opportunity to carry out more extensive and in-depth cooperation in the medical and health fields. Japan's Hainan Chamber of Commerce will serve as a bridge between Lecheng and Japanese enterprises, and introduce more medical institutions, medical technologies and devices and drugs to land in Lecheng.
This promotion conference is guided by the Development and Reform Commission of Hainan Province, Hainan Provincial Health Commission and Hainan Medical Products Administration, sponsored by Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration, assisted by Hainan Provincial Bureau of International Economic Development and Hainan Overseas Chinese Affairs Office, and supported by Hong Kong WinHealth Pharma Group Co. Limited, Laox Co.,Ltd, Mizuho Bank, Ltd. and EPS International Holdings Co, Ltd.
Fan Bin, Director of Lecheng Medical Products Administration, Fu Gan, member of the Party Committee and Secretary of the Discipline Inspection Commission of Lecheng Pilot Zone Administration, Chen Wei, deputy director of the Overseas Chinese Affairs Management Division II of the United Front Work Department of Hainan Provincial Party Committee, and Li Saimei, Tier 3 researcher of the Overseas Chinese Affairs Management Division I of the United Front Work Department of Hainan Provincial Party Committee; more than 60 pharmaceutical enterprises and medical institutions, including Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co., Ltd., ONO Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd., Kyowa Kirin Co Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co.，Ltd., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Towako Group, Tsurumatsu Health, Minophagen Pharmaceutical Co., Ltd, more than ten organizations and associations, including Japan Consulate General in Guangzhou, the Japanese Chamber of Commerce and Industry in China, Beijing Chamber of Commerce in Japan, Japan International Medical Policy Agency, Japan Council of International Educational Institutions, Japan-China Youth Economic and Cultural Exchange Association, Hainan Chamber of Commerce in Japan, etc. and 8 investment companies， including Guangzhou Esprit Business Consulting Co., Ltd., Mizuho Bank, Ltd. and Taiho Pharmaceutical of Beijing Co., Ltd., attended the conference.